Connor Clark & Lunn Investment Management Ltd. Raises Holdings in Haemonetics Co. (NYSE:HAE)

Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Haemonetics Co. (NYSE:HAE) by 14.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 252,142 shares of the medical instruments supplier’s stock after buying an additional 31,689 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Haemonetics were worth $19,687,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in HAE. FMR LLC grew its holdings in shares of Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after purchasing an additional 521,640 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after buying an additional 363,702 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Haemonetics by 29.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after buying an additional 250,833 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Haemonetics during the fourth quarter worth about $19,002,000. Finally, Boston Trust Walden Corp boosted its stake in shares of Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after buying an additional 106,114 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE stock opened at $65.85 on Friday. The firm has a 50 day moving average of $68.90 and a 200-day moving average of $75.49. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company has a market cap of $3.31 billion, a price-to-earnings ratio of 25.92, a PEG ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, equities analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HAE shares. Raymond James reiterated a “strong-buy” rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Needham & Company LLC decreased their target price on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.